Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.58 |
| ▸ | RAB9A | P51151 | 7/20 | 0.58 |
| ▸ | POLB | P06746 | 5/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19940614 | 0.87 | ALDH1A1 (0.51) | NPC1RAB9APOLBTDP1SMN1; SMN2 | |
| SCHEMBL2541634 | 0.85 | ALDH1A1 (0.60) | NPC1RAB9APOLBTDP1SMN1; SMN2 | |
| SCHEMBL15926026 | 0.84 | ALDH1A1 (0.49) | NPC1RAB9APOLBTDP1SMN1; SMN2 | |
| SCHEMBL28244873 | 0.84 | ALDH1A1 (0.49) | NPC1RAB9APOLBTDP1SMN1; SMN2 | |
| SCHEMBL14062281 | 0.83 | SMN1; SMN2 (0.48) | NPC1RAB9APOLBTDP1SMN1; SMN2 | |
| SCHEMBL19002709 | 0.83 | SMN1; SMN2 (0.67) | NPC1RAB9APOLBSMN1; SMN2KMT2A | |
| SCHEMBL17695022 | 0.83 | NPC1 (0.59) | NPC1RAB9APOLBTDP1SMN1; SMN2 | |
| SCHEMBL3191767 | 0.81 | NPC1 (0.61) | NPC1RAB9APOLBTDP1SMN1; SMN2 | |
| SCHEMBL22856757 | 0.81 | HTT (0.47) | NPC1RAB9APOLBTDP1SMN1; SMN2 | |
| SCHEMBL7498200 | 0.81 | L3MBTL1 (0.59) | NPC1RAB9APOLBSMN1; SMN2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4678636-A1 | METHOD FOR PRODUCING FURAN-2,5-DICARBOXYLIC ACID | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-01-14 | — | — | EP | disclosed |
| US-20260001855-A1 | METHOD FOR PRODUCING FURAN-2,5-DICARBOXYLIC ACID | MITSUBISHI GAS CHEMICAL COMPANY, INC. (JP) | 2026-01-01 | — | — | US | disclosed |
| US-20250346568-A1 | PRODUCING 2,5-FURANDICARBOXYLIC ACID IN THE PRESENCE OF MODIFYING ACID | FURANIX TECHNOLOGIES BV (NL) | 2025-11-13 | — | — | US | disclosed |
| EP-4540236-A1 | PRODUCING 2,5-FURANDICARBOXYLIC ACID FROM MIXED FEED | Furanix Technologies B.V. (NL) | 2025-04-23 | — | — | EP | disclosed |
| EP-4540235-A1 | PRODUCING 2,5-FURANDICARBOXYLIC ACID IN THE PRESENCE OF MODIFYING ACID | Furanix Technologies B.V. (NL) | 2025-04-23 | — | — | EP | disclosed |
| WO-2023242152-A1 | PRODUCING 2,5-FURANDICARBOXYLIC ACID FROM MIXED FEED | FURANIX TECHNOLOGIES B.V. (NL) | 2023-12-21 | — | — | WO | disclosed |
| WO-2023242150-A1 | PRODUCING 2,5-FURANDICARBOXYLIC ACID IN THE PRESENCE OF MODIFYING ACID | FURANIX TECHNOLOGIES B.V. (NL) | 2023-12-21 | — | — | WO | disclosed |
| CN-115073401-B | 2,3 '-bisfuran compound, 2,3' -oligomeric furan compound, and preparation methods and applications thereof | 华南理工大学 | 2023-07-14 | — | — | CN | disclosed |
| CN-115073401-A | 2,3 '-difuran compound and 2,3' -oligofuran compound, and preparation method and application thereof | 华南理工大学 | 2022-09-20 | — | — | CN | disclosed |
| EP-3666764-A1 | METHOD FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND FOR THE PREPARATION OF THE DIALKYL ESTER OF 2,5-FURANDICARBOXYLIC ACID | Furanix Technologies B.V (NL) | 2020-06-17 | — | — | EP | disclosed |
| US-20120271060-A1 | METHOD FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND FOR THE PREPARATION OF THE DIALKYL ESTER OF 2,5-FURANDICARBOXYLIC ACID | FURANIX TECHNOLOGIES B.V. (NL) | 2012-10-25 | — | — | US | disclosed |
| CN-102459214-A | Oxidation of furfural compounds | ARCHER DANIELS MIDLAND CO | 2012-05-16 | — | — | CN | disclosed |
| EP-2430010-A2 | OXIDATION OF FURFURAL COMPOUNDS | Archer Daniels Midland Company (US) | 2012-03-21 | — | — | EP | disclosed |
| US-20120059178-A1 | OXIDATION OF FURFURAL COMPOUNDS | ARCHER DANIELS MIDLAND COMPANY (US) | 2012-03-08 | — | — | US | disclosed |
| WO-2010132740-A2 | OXIDATION OF FURFURAL COMPOUNDS | ARCHER DANIELS MIDLAND COMPANY (US) | 2010-11-18 | — | — | WO | disclosed |
| US-6077952-A | Cephaloporins and homologues | PFIZER INC. (US) | 2000-06-20 | — | — | US | disclosed |
| US-6020329-A | Cephaloporins and homologues, preparations and pharmaceutical compositions | PZIFER INC. (US) | 2000-02-01 | — | — | US | disclosed |
| US-6001997-A | Cephalosporins and homologues, preparations and pharmaceutical compositions | BATESON JOHN HARGREAVES (GB) | 1999-12-14 | — | — | US | disclosed |
| EP-0540609-A1 | CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | PFIZER INC. (US) | 1993-05-12 | — | — | EP | disclosed |
| WO-1992001696-A1 | CEPHALOSPORINS AND HOMOLOGUES, PREPARATIONS AND PHARMACEUTICAL COMPOSITIONS | BEECHAM GROUP PLC (GB) | 1992-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120059178-A1 | OXIDATION OF FURFURAL COMPOUNDS | ETFA, ETFB, FTO | NPC1 2419/4885RAB9A 3895/4885POLB 2836/4885 |
| US-20260001855-A1 | METHOD FOR PRODUCING FURAN-2,5-DICARBOXYLIC ACID | HAO2, MDH2, NOX5 | NPC1 3803/4885RAB9A 2079/4885POLB 1610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.